Category |
Endocrinology & Metabolism |
Manuscript Type |
Review |
Article Title |
Hepatocyte growth factor, a biomarker of macroangiopathy in diabetes mellitus
|
Manuscript Source |
Invited Manuscript |
All Author List |
Hiroyuki Konya, Masayuki Miuchi, Kahori Satani, Satoshi Matsutani, Taku Tsunoda, Yuzo Yano, Tomoyuki Katsuno, Tomoya Hamaguchi, Jun-Ichiro Miyagawa and Mitsuyoshi Namba |
Funding Agency and Grant Number |
|
Corresponding Author |
Hiroyuki Konya, MD, PhD, Department of Internal Medicine, Ashiya Municipal Hospital, 39-1, Asahigaoka-cho, Ashiya, Hyogo 659-8502, Japan. h-dyer@mvi.biglobe.ne.jp |
Key Words |
Hepatocyte growth factor; Diabetes mellitus; Carotid atherosclerosis; Macroangiopathy; Biomarker |
Core Tip |
Hepatocyte growth factor (HGF) has been a mesenchymal-derived polyphenic factor which modulates development, motion, and morphosis of diverse cells, and has been regarded as a humor intermediator of epithelial-mesenchymal interplays. The serum levels of HGF in diabetes mellitus (DM) subjects might be assayed by balancing of stimulators (hypertension, atheromatous arteriosclerosis, etc.) and suppressors (hyperglycemia, transforming growth factor-, angiotensin II, etc.). The elevated serum level of HGF might have been regarded as an indicator of the DM involvements seriousness. Accordingly, the concentration of serum HGF might be a new and meaningful biomarker of macroangiopathy in DM subjects. |
Publish Date |
2014-08-17 13:16 |
Citation |
Konya H, Miuchi M, Satani K, Matsutani S, Tsunoda T, Yano Y, Katsuno T, Hamaguchi T, Miyagawa JI, Namba M. Hepatocyte growth factor, a biomarker of macroangiopathy in diabetes mellitus. World J Diabetes 2014; 5(5): 678-688 |
URL |
http://www.wjgnet.com/1948-9358/full/v5/i5/678.htm |
DOI |
http://dx.doi.org/10.4239/wjd.v5.i5.678 |